Targeting accelerated progress at the IPAC-RS Nasal Innovation Forum 2025
Explore how Nanopharm presented strategies for accelerating patient-centric nasal product development at the IPAC-RS Nasal Innovation Forum 2025. Dive into key insights on regulatory science, advanced bioequivalence methods, and targeted drug delivery.
Aligning Alternative Bioequivilence with U.S. FDA: Advancing aerosol dose collection to enhance in vitro dissolution studies
Discover how Nanopharm’s DissoHale system advances aerosol dose collection and dissolution testing to support FDA-aligned alternative bioequivalence for OIDPs.
Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques
Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques
GDUFA: FDA adds further weight to modelling and simulation’s role in bioequivalence
GDUFA 2026: FDA strengthens role of modeling & simulation for inhaled generic drug bioequivalence. Learn how this shift enhances efficiency for OINDP development.
Optimizing OINDP Regulatory Paths With Model Master Files (MMF)
Streamline OINDP regulatory submissions with Model Master Files—confidential, reusable models that accelerate drug development and U.S. FDA review.
Accelerating OINDP Development with Nanopharm
Discover how Nanopharm, supports OINDP development from preclinical to CGMP with SmartTrack™, in silico modeling, and regulatory expertise.
Advancing Alternative Bioequivalence for OINDPs
Nanopharm & Fluidda explore FDA’s progress in alternative bioequivalence for OINDPs, Model Master Files (MMF), and future regulatory pathways.
In Silico Bioequivalence Beyond Generic Drug Development
Nanopharm & Fluidda discuss FDA’s in silico bioequivalence methods for alternative pathways beyond generics in inhalation drug development.
Nanopharm & Fluidda Discuss FDA’s New Inhaled Product Guidelines
Explore how alternative bioequivalence methods, including computational fluid dynamics and in silico modeling, are shaping the future of generic drug approval.
Nanopharm Announces Exclusive Collaboration With Fluidda To Accelerate Regulatory Pathway For OINDP Using SmartTrack
Crystal Lake, Illinois, September 22, 2022 – Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE: ATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.
